{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:06:06Z","timestamp":1758636366974},"reference-count":27,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2022.13506","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T08:25:19Z","timestamp":1663316719000},"source":"Crossref","is-referenced-by-count":1,"title":["Study on the method to avoid infusion\u2011site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells"],"prefix":"10.3892","volume":"24","author":[{"given":"Miho","family":"Yamasaki","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chugoku Rosai Hospital, Kure, Hiroshima 737\u20110193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Oda","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20110112, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ichinose","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chugoku Rosai Hospital, Kure, Hiroshima 737\u20110193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Mizuguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chugoku Rosai Hospital, Kure, Hiroshima 737\u20110193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chugoku Rosai Hospital, Kure, Hiroshima 737\u20110193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Omoda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chugoku Rosai Hospital, Kure, Hiroshima 737\u20110193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Mori","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20110112, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yorinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Information Analytics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729\u20110292, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Chugoku Rosai Hospital, Kure, Hiroshima 737\u20110193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Murakami","sequence":"additional","affiliation":[{"name":"Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737\u20110112, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"key20221013104736_b1-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1188\/16.CJON.555-556","article-title":"Benefits and Risks of fosaprepitant in patients receiving emetogenic regimens","volume":"20","author":"Pritchett","year":"2016","journal-title":"Clin J Oncol Nurs"},{"key":"key20221013104736_b2-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"390","DOI":"10.7150\/jca.7706","article-title":"Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients","volume":"5","author":"Sato","year":"2014","journal-title":"J Cancer"},{"key":"key20221013104736_b3-ol-24-05-13506","first-page":"379","article-title":"Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens","volume":"35","author":"Fujii","year":"2015","journal-title":"Anticancer Res"},{"key":"key20221013104736_b4-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00520-014-2326-9","article-title":"An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy","volume":"23","author":"Hegerova","year":"2015","journal-title":"Support Care Cancer"},{"key":"key20221013104736_b5-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2217\/fon-2018-0662","article-title":"Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: A retrospective study","volume":"15","author":"Boccia","year":"2019","journal-title":"Future Oncol"},{"key":"key20221013104736_b6-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00520-013-2106-y","article-title":"Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant","volume":"22","author":"Lundberg","year":"2014","journal-title":"Support Care Cancer"},{"key":"key20221013104736_b7-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1177\/1078155218769347","article-title":"Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant","volume":"25","author":"Chau","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"key20221013104736_b8-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2147\/DDDT.S155875","article-title":"Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: A phase I, open-label, randomized, two-way crossover evaluation","volume":"12","author":"Ottoboni","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"key20221013104736_b9-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.2217\/fon-2018-0311","article-title":"Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects","volume":"14","author":"Ottoboni","year":"2018","journal-title":"Future Oncol"},{"key":"key20221013104736_b10-ol-24-05-13506","first-page":"43","article-title":"Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant","volume":"11","author":"Yamasaki","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"key20221013104736_b11-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"126","DOI":"10.15344\/2456-3501\/2017\/126","article-title":"Biopharmaceutical properties of tubeimoside-1: A cytotoxic amphipathic cyclic bisdesmoside","volume":"2","author":"Oda","year":"2017","journal-title":"Int J Clin Pharmacol Pharmacother"},{"key":"key20221013104736_b12-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"19","DOI":"10.31768\/2312-8852.2018.40(1):19-23","article-title":"Characterization of the cytotoxic effects of the combination of cisplatin and flavanol (\u2212)-epicatechin on human lung cancer cell line A549. An isobolographic approach","volume":"40","author":"Varela-Castillo","year":"2018","journal-title":"Exp Oncol"},{"key":"key20221013104736_b13-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1124\/jpet.119.261735","article-title":"Isobolographic analysis of antiseizure activity of the GABA type A receptor-modulating synthetic neurosteroids brexanolone and ganaxolone with tiagabine and midazolam","volume":"372","author":"Chuang","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"key20221013104736_b14-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/acsmedchemlett.0c00640","article-title":"Discovery of orally active and nonsteroidal farnesoid X receptor (FXR) antagonist with propensity for accumulation and responsiveness in ileum","volume":"12","author":"Teno","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"key20221013104736_b15-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2147\/TCRM.S2345","article-title":"Prevention of chemotherapy-induced nausea and vomiting: Focus on fosaprepitant","volume":"4","author":"Olver","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"key20221013104736_b16-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.toxlet.2005.07.001","article-title":"In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride","volume":"160","author":"Fotakis","year":"2006","journal-title":"Toxicol Lett"},{"key":"key20221013104736_b17-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/antiox6040089","article-title":"Trans-plasma membrane electron transport and ascorbate efflux by skeletal muscle","volume":"6","author":"Eccardt","year":"2017","journal-title":"Antioxidants (Basel)"},{"key":"key20221013104736_b18-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"e0231634","DOI":"10.1371\/journal.pone.0231634","article-title":"Mind your assays: Misleading cytotoxicity with the WST-1 assay in the presence of manganese","volume":"15","author":"Scarcello","year":"2020","journal-title":"PLoS One"},{"key":"key20221013104736_b19-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"11345","DOI":"10.3390\/molecules200611345","article-title":"Characterization and pharmacokinetic study of aprepitant solid dispersions with soluplus\u00ae","volume":"20","author":"Liu","year":"2015","journal-title":"Molecules"},{"key":"key20221013104736_b20-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ajpath.2019.07.021","article-title":"Nanomechanics of the endothelial glycocalyx: From structure to function","volume":"190","author":"Cosgun","year":"2020","journal-title":"Am J Pathol"},{"key":"key20221013104736_b21-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1080\/10826076.2013.803202","article-title":"Development and validation of a stability-indicating RP-LC method for the determination of anticancer drug epirubicin in pharmaceuticals","volume":"37","author":"Kurbanoglu","year":"2014","journal-title":"J Liq Chromatogr Relat Technol"},{"key":"key20221013104736_b22-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1023\/A:1015935031933","article-title":"Phosphatidylserine as a determinant for the tissue distribution of weakly basic drugs in rats","volume":"7","author":"Yata","year":"1990","journal-title":"Pharm Res"},{"key":"key20221013104736_b23-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1517\/17425255.2011.548805","article-title":"Role of phosphatidylserine binding in tissue distribution of amine-containing basic compounds","volume":"7","author":"Murakami","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key20221013104736_b24-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5172\/conu.17.3.264","article-title":"Flushing an i.v. line: A simple but potentially costly procedure for both patient and health unit","volume":"17","author":"Wotton","year":"2004","journal-title":"Contemp Nurse"},{"key":"key20221013104736_b25-ol-24-05-13506","first-page":"CD004593","article-title":"Continuous infusion versus intermittent flushing to prevent loss of function of peripheral intravenous catheters used for drug administration in newborn infants","author":"Flint","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key20221013104736_b26-ol-24-05-13506","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1515\/jpm-2011-1000","article-title":"Intermittent flushing improves cannula patency compared to continuous infusion for peripherally inserted venous catheters in newborns: Results from a prospective observational study","volume":"40","author":"Perez","year":"2012","journal-title":"J Perinat Med"},{"key":"key20221013104736_b27-ol-24-05-13506","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jpen.1455","article-title":"American society for parenteral and enteral nutrition guidelines for the selection and care of central venous access devices for adult home parenteral nutrition administration","volume":"43","author":"Kovacevich","year":"2019","journal-title":"JPEN J Parenter Enteral Nutr"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T01:48:25Z","timestamp":1701049705000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2022.13506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9,16]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2022.13506","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"article-number":"386"}}